Preview

Современная ревматология

Расширенный поиск

Преимущества лечения остеоартрита комбинированным препаратом замедленного действия

https://doi.org/10.14412/1996-7012-2021-2-126-131

Полный текст:

Аннотация

В обзоре обсуждаются вопросы эффективности комбинированных препаратов хондроитина и глюкозамина (ГЛ) при лечении остеоартрита (ОА). Благодаря высокому уровню безопасности и плейотропным эффектам эти препараты могут применяться у пациентов с ОА (в первую очередь с метаболическим и воспалительным фенотипами), имеющих коморбидную патологию. Описано влияние пероральных форм ГЛ и хондроитина на микробиом кишечника: регулирование состава, метаболической и иммунологической активности кишечной микробиоты. Отмечена взаимосвязь между регулярным приемом препаратов хондроитина и ГЛ и снижением общей смертности и смертности от сердечно-сосудистых заболеваний, а также риска развития онкологических заболеваний.

Об авторе

Е. В. Зонова
ФГБОУ ВО «Новосибирский государственный медицинский университет» Минздрава России
Россия

Елена Владимировна Зонова

630091, Новосибирск, Красный проспект, 52



Литература

1. Bruyere O, Honvo G, Veronese N, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Semin Arthritis Rheum. 2019; 49(3):337-50. doi: 10.1016/j.semarthrit.2019.04.008.

2. Brandä o GC, Korukian M, Brandä o DC, Mainine S, Souza Junior AP. Association of glucosamine sulfate and chondroitin sulfate for patients with osteoarthritis of the knee. Rev Bras Med. 2009;66(11):405-8

3. Lomonte ABV, Mendonca JA, de Castro BG, Castro ML. Multicenter, randomized, double-blind clinical trial to evaluate efficacy and safety of combined glucosamine sulfate and chondroitin sulfate capsules for treating knee osteoarthritis. Adv Rheumatol. 2018 Dec 5;58(1):41. doi: 10.1186/s42358-018-0041-9.

4. Лила АМ, Алексеева ЛИ, Бабаева АР и др. Возможности фармакологического лечения остеоартрита: фокус на симптоматические медленно действующие препараты (SYSADOA) и индивидуальные особенности пациента. Резолюция международного совещания экспертов. Современная ревматология. 2019;13(4):143-7. doi: 10.14412/1996-7012-2019-4-143-147

5. Zeng C, Wei J, Li H, et al. Effectiveness and safety of Glucosamine, chondroitin, the two in combination, or celecoxib in the treatment of osteoarthritis of the knee. Sci Rep. 2015 Nov 18;5:16827. doi: 10.1038/srep16827.

6. Martel-Pelletier J, Roubille C, Abram F, et al. First-line analysis of the effects of treatment on progression of structural changes in knee osteoarthritis over 24 months: data from the osteoarthritis initiative progression cohort. Ann Rheum Dis. 2015 Mar;74(3): 547-56. doi: 10.1136/annrheumdis-2013-203906. Epub 2013 Dec 13.

7. Henrotin Y, Mathy M, Sanchez C, Lambert C. Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations. Ther Adv Musculoskelet Dis. 2010 Dec;2(6):335-48. doi: 10.1177/1759720X10383076.

8. Fardellone P, Zaim M, Saurel AS, Maheu E. Comparative efficacy and safety study of two chondroitin sulfate preparations from different origin (avian and bovine) in symptomatic osteoarthritis of the knee. Open Rheumatol J. 2013;7:1-12. doi: 10.2174/1874312901307010001. Epub 2013 Feb 8.

9. Lomonte ABV, Gimenez E, Carlos da Silva A, et al. Treatment of knee osteoarthritis with a new formulation of a fixed-dose combination of glucosamine sulfate and bovine chondroitin: a multicenter, randomized, single-blind, non-inferiority clinical trial. Adv Rheumatol. 2021 Jan 19; 61(1):7. doi: 10.1186/s42358-021-00165-9.

10. Arden NK, Perry TA, Bannuru RR, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021 Jan;17(1):59-66. doi: 10.1038/s41584-020-00523-9.

11. Roman-Blas JA, Castaneda S, Sanchez-Pernaute O, et al; CS/GS Combined Therapy Study Group. Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Arthritis Rheumatol. 2017 Jan;69(1):77-85. doi: 10.1002/art.39819.

12. Hochberg MC, Martel-Pelletier J, Monfort J, et al. Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib. Ann Rheum Dis. 2016;75(1):37-44. doi: 10.1136/annrheumdis-2014-206792.

13. Sawitzke AD, Shi H, Finco MF et al. The effect of glucosamine and/or chondroitin sulfate on the progression of knee osteoarthritis: a report from the glucosamine/chondroitin arthritis intervention trial. Arthritis Rheum. 2008 Oct;58(10):3183-91. doi: 10.1002/art.23973.

14. Sawitzke AD, Shi H, Finco MF, et al. Clinical efficacy and safety of glucosamine, chondroitin sulphate, their combination, celecoxib or placebo taken to treat osteoarthritis of the knee: 2-year results from GAIT. Ann Rheum Dis. 2010 Aug;69(8): 1459-64. doi: 10.1136/ard.2009.120469. Epub 2010 Jun 4.

15. Towheed TE, Anastassiades T. Glucosamine therapy for osteoarthritis: an update. J Rheumatol. 2007 Sep;34(9):1787-90.

16. Piperno M, Reboul P, Hellio Le Graverand MP, et al. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage. 2000 May;8(3): 207-12. doi: 10.1053/joca.1999.0291.

17. Aghazadeh-Habashi A, Jamali F. The glucosamine controversy: a pharmacokinetic issue. J Pharm Pharm Sci. 2011;14(2): 264-73. doi: 10.18433/j3xg6f.

18. Алексеева ЛИ, Кашеварова НГ, Шарапова ЕП и др. Сравнение постоянного и интермиттирующего лечения больных остеоартрозом коленных суставов комбинированным препаратом «Терафлекс». Научно-практическая ревматология. 2008;(3): 68-72.

19. Лила АМ, Алексеева ЛИ, Телышев КА и др. Эффективность лечения остеоартрита коленного и тазобедренного суставов комбинированным препаратом хондроитина сульфата и глюкозамина гидрохлорида: промежуточные результаты российского наблюдательного исследования. Современная ревматология. 2020; 14(3):71-8. doi: 10.14412/1996-7012-2020-3-71-78

20. Deveza LA, Nelson AE, Loeser RF. Phenotipes of osteoarthritis- current state and future implications. Clin Exp Rheumatol. Sep-Oct 2019;37 Suppl 120(5):64-72. Epub 2019 Oct 15.

21. Lentz TA, Hellkamp AS, Bhavsar NA, et al. Assessment of Common Comorbidity Phenotypes Among Older Adults With Knee Osteoarthritis to Inform Integrated Care Models. Mayo Clin Proc Inn Qual Out. XXX 2020;nn(n):1-12 n. doi: 10.1016/j.mayocpiqo.2020.09.011

22. Courties A, Berenbaum F, Sellam J. The Phenotypic Approach to Osteoarthritis: A Look at Metabolic Syndrome-Associated Osteoarthritis. Joint Bone Spine. 2019;86(6): 725-30. doi: 10.1016/j.jbspin.2018.12.005.

23. Zhuo Q, Yang W, Chen J, Wang Y. Metabolic syndrome meets osteoarthritis. Nat Rev Rheumatol. 2012;8(12):729-37. doi: 10.1038/nrrheum.2012.135.

24. Zonova EV, Lykov A, Trifonova EP, Sazonova OV. Characterization of osteoarthritis in patients with diabetes mellitus type 2. Integr Mol Med. 2017; 3(3):649-653.

25. Farnaghi S, Prasadam I, Cai G, et al. Protective effects of mitochondria-targeted antioxidants and statins on cholesterolinduced osteoarthritis. FASEB J. 2017 Jan; 31(1):356-67. doi: 10.1096/fj.201600600R. Epub 2016 Oct 13.

26. Gkretsi V, Simopoulou T, Tsezou A. Lipid metabolism and osteoarthritis: lessons from atherosclerosis. Prog Lipid Res. 2011 Apr;50(2):133-40. doi: 10.1016/j.plipres.2010.11.001. Epub 2010 Nov 27.

27. Courties A, Sellam J, Berenbaum F. Metabolic syndrome-associated osteoarthritis. Curr Opin Rheumatol. 2017 Mar;29(2): 214-22. doi: 10.1097/BOR.0000000000000373.

28. Li W, Kobayashi T, Moroi S, et al. Anti-obesity effects of chondroitin sulfate oligosaccharides from the skate Raja pulchra. Carbohydr Polym. 2019 Jun 15;214:303-10. doi: 10.1016/j.carbpol.2019.03.025. Epub 2019 Mar 12.

29. Pal D, Saha S. Chondroitin: a natural biomarker with immense biomedical applications. RSC Adv. 2019;9:28061-77.

30. Angelides S, Manolios N. Correspondence on 'Glucosamine and O-GlcNAcylation: a novel immunometabolic therapeutic target for OA and chronic, lowgrade systemic inflammation?'.Ann Rheum Dis. 2021 Jan 27;annrheumdis-2020-219694. doi: 10.1136/annrheumdis-2020-219694. Online ahead of print.

31. Kantor ED, O'Connell K, Du M, et al. Glucosamine and Chondroitin Use in Relation to C-Reactive Protein Concentration: Results by Supplement Form, Formulation, and Dose. J Altern Complement Med. 2021 Feb;27(2):150-9. doi: 10.1089/acm.2020.0283. Epub 2020 Dec 7.

32. Hao X, Shang X, Liu J, et al. The gut microbiota in osteoarthritis: where do we stand and what can we do? Arthritis Res Ther. 2021 Jan 27;23(1):42. doi: 10.1186/s13075-021-02427-9.

33. Shmagel A, Demmer R, Knights D, et al. The Effects of Glucosamine and Chondroitin Sulfate on Gut Microbial Composition: A Systematic Review of Evidence from Animal and Human Studies. Nutrients. 2019 Jan 30;11(2):294. doi: 10.3390/nu11020294.

34. Liu F, Zhang N, Li Z, et al. Chondroitin sulfate disaccharides modified the structure and function of the murine gut microbiome under healthy and stressed conditions. Sci Rep. 2017 Jul 28;7(1):6783. doi: 10.1038/s41598-017-05860-6.

35. Coulson S, Butt H, Vecchio P, et al. Green-lipped mussel extract (Perna canaliculus) and glucosamine sulphate in patients with knee osteoarthritis: therapeutic efficacy and effects on gastrointestinal microbiota profiles. Inflammopharmacology. 2013 Feb; 21(1):79-90. doi: 10.1007/s10787-012-0146-4. Epub 2012 Jul 22.

36. Lee HS, Han SY, Ryu KY, Kim DH. The degradation of glycosaminoglycans by intestinal microflora deteriorates colitis in mice. Inflammation. 2009 Feb;32(1):27-36. doi: 10.1007/s10753-008-9099-6.

37. Sicard JF, Vogeleer P, Le Bihan G, et al. N-Acetyl-glucosamine influences the biofilm formation of Escherichia coli. Gut Pathog. 2018 Jun 22;10:26. doi: 10.1186/s13099-018-0252-y. eCollection 2018.

38. Biver E, Berenbaum F, Valdes AM, et al. Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev. 2019 Nov;55:100946. doi: 10.1016/j.arr.2019.100946. Epub 2019 Aug 19.

39. Ma H, Li X, Sun D, et al. Association of habitual glucosamine use with risk of cardiovascular disease: prospective study in UK Biobank. BMJ. 2019 May 14;365:l1628. doi: 10.1136/bmj.l1628.

40. Bell GA, Kantor ED, Lampe JW, et al. Use of glucosamine and chondroitin in relation to mortality. Eur J Epidemiol. 2012 Aug; 27(8):593-603. doi: 10.1007/s10654-012-9714-6. Epub 2012 Jul 25.

41. Satia JA, Littman A, Slatore CG, et al. Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study. Cancer Epidemiol Biomarkers Prev. 2009 May;18(5): 1419-28. doi: 10.1158/1055-9965.EPI09-0038.

42. King DE, Xiang J. Glucosamine/ Chondroitin and Mortality in a US NHANES Cohort. J Am Board Fam Med. Nov-Dec 2020;33(6):842-7. doi: 10.3122/jabfm.2020.06.200110.

43. Reddy SVLN, Vantaku KS, Sowmya K, et al. Prospective study on assessment of efficacy of etoricoxib versus etoricoxib with combination of glucosamine and chondroitin in primary osteoarthritis of knee. IP Int J Orthop Rheumatol. 2020;6(1):18-22.

44. Al-Omari B, McMeekin P, Bate A. Systematic Review of Studies Using Conjoint Analysis Techniques to Investigate Patients' Preferences Regarding Osteoarthritis Treatment. Patient Prefer Adherence. 2021 Feb 3;15:197-211. doi: 10.2147/PPA.S287322. eCollection 2021.

45. Rubio-Terres С, Pineda MB, Herrero M, et al. Analysis of the Health and Budgetary Impact of Chondroitin Sulfate Prescription in the Treatment of Knee Osteoarthritis Compared to NSAIDs and COXIBs. Clinicoecon Outcomes Res. 2020 Sep 14;12: 505-514. doi: 10.2147/CEOR.S265994. eCollection 2020.


Для цитирования:


Зонова Е.В. Преимущества лечения остеоартрита комбинированным препаратом замедленного действия. Современная ревматология. 2021;15(2):126-131. https://doi.org/10.14412/1996-7012-2021-2-126-131

For citation:


Zonova E.V. Advantages of osteoarthritis combined treatment with symptomatic slow-acting drugs. Modern Rheumatology Journal. 2021;15(2):126-131. (In Russ.) https://doi.org/10.14412/1996-7012-2021-2-126-131

Просмотров: 43


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)